Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 347

Results For "lab"

5008 News Found

Cytel unlocks innovative clinical development expertise for APAC biopharma sector
Biotech | September 15, 2022

Cytel unlocks innovative clinical development expertise for APAC biopharma sector

Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.


NMDP focuses on smooth transition to licensing of Class-A and B medical devices
News | September 15, 2022

NMDP focuses on smooth transition to licensing of Class-A and B medical devices

The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017


AstraZeneca launches up-skilling program iPHARMACY
News | September 15, 2022

AstraZeneca launches up-skilling program iPHARMACY

The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala


Mandaviya launches NLEM 2022
Policy | September 14, 2022

Mandaviya launches NLEM 2022

This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens


Philips Foundation and RAD-AID International embark on a multi-year cross-continental partnership
News | September 14, 2022

Philips Foundation and RAD-AID International embark on a multi-year cross-continental partnership

Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas


AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


Medvarsity partners Wolters Kluwer to improve learning outcomes
News | September 13, 2022

Medvarsity partners Wolters Kluwer to improve learning outcomes

This association between the two esteemed organizations allows Medvarsity to significantly – and positively – impact healthcare education


Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda  for urothelial cancer
Clinical Trials | September 13, 2022

Seagen, Astellas and Merck announce results of clinical trial investigating PADCEV with Keytruda for urothelial cancer

Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab


Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone
Clinical Trials | September 12, 2022

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials


Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA
Clinical Trials | September 12, 2022

Merck and Eisai present results from Phase 3 LEAP-002 Trial evaluating KEYTRUDA

Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022